Maria Natalia Gandur Quiroga: Promising results for zanzalintinib in advanced clear cell renal cell carcinoma treatment presented by Sumanta K. Pal
Quoting Maria Natalia Gandur Quiroga on X/Twitter:
“Exciting updates from The Kidney Cancer Association’s International Kidney Cancer Symposium 2023 (IKCSNA23)! Promising results for zanzalintinib in advanced clear cell renal cell carcinoma treatment presented by Sumanta K. Pal.
1. Antitumor Activity:
- Significant responses in heavily pretreated patients
- Disease control achieved in both cabozantinib-exposed and naive groups
- Overall Response Rate (ORR) of 38%
2. Patient Characteristics:
- Aggressive phenotype noted with 38% having liver and bone metastases
- 41% received at least 3 prior lines of therapy
- High prior exposure to immune checkpoint inhibitors and VEGF TKIs
3. Disease Control and Response Rates:
- Impressive Disease Control Rate of 88%
- ORR of 24% for cabozantinib-exposed, 57% for cabozantinib-naive
- Responses in 80% of patients with prior VEGF TKIs
4. Duration of Response (DOR):
- Median DOR: 7.4 months for cabozantinib-naive
- DOR not reached in cabozantinib-exposed
- 75% responses at the first post-baseline assessment
5. Safety Profile:
- No grade 4/5 treatment-related adverse events
- Lower rates of side effects compared to standard TKIs
- Minimal discontinuation for adverse events
6. Future Prospects:
- Zanzalintinib in combinations with immune checkpoint inhibitors
- Phase III trial with nivolumab underway
- Potential for refractory kidney cancer, even in those who progressed on cabozantinib
Stay tuned for more updates on zanzalintinib’s potential in kidney cancer and advanced solid tumors! Read more here.
Source: Maria Natalia Gandur Quiroga/Twitter
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023